13 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 33397422 | Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy. | 2021 Jan 4 | 3 |
2 | 33413292 | Dermatomyositis associated with prostate adenocarcinoma with neuroendocrine differentiation. | 2021 Jan 7 | 1 |
3 | 28094250 | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. | 2017 Jun | 2 |
4 | 28882187 | Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation. | 2017 Sep 7 | 1 |
5 | 29020683 | Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy. | 2017 | 2 |
6 | 30333445 | [A CASE OF PROSTATE CANCER WITH SECONDARY HYPOGONADISM]. | 2017 | 1 |
7 | 26529826 | New developments in metastatic prostate cancer therapy. | 2015 Apr | 1 |
8 | 24418913 | Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. | 2014 Mar | 1 |
9 | 24566948 | Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? | 2014 Jul | 1 |
10 | 21561791 | Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. | 2013 Jul | 2 |
11 | 23552872 | Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. | 2013 Jul | 1 |
12 | 19449118 | Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. | 2010 Mar | 1 |
13 | 17784982 | What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml? | 2007 Aug | 1 |